Disease burden of chronic hepatitis C in Brazil

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFERREIRA, Paulo Roberto Abrao
dc.contributor.authorBRANDAO-MELLO, Carlos Eduardo
dc.contributor.authorESTES, Chris
dc.contributor.authorGONCALES JUNIOR, Fernando Lopes
dc.contributor.authorCOELHO, Henrique Sergio Moraes
dc.contributor.authorRAZAVI, Homie
dc.contributor.authorCHEINQUER, Hugo
dc.contributor.authorWOLFF, Fernando Herz
dc.contributor.authorFERRAZ, Maria Lucia Gomes
dc.contributor.authorPESSOA, Mario Guimardes
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.date.accessioned2015-10-26T16:27:51Z
dc.date.available2015-10-26T16:27:51Z
dc.date.issued2015
dc.description.abstractBackground: Hepatitis C virus infection is a major cause of cirrhosis; hepatocellular carcinoma; and liver transplantation. The aim of this study was to estimate hepatitis C virus disease progression and the burden of disease from a nationwide perspective. Methods: Using a model developed to forecast hepatitis C virus disease progression and the number of cases at each stage of liver disease; hepatitis C virus-infected population and associated disease progression in Brazil were quantified. The impact of two different strategies was compared: higher sustained virological response and treatment eligibility rates (1) or higher diagnosis and treatment rates associated with increased sustained virological response rates (2). Results: The number of infected individuals is estimated to decline by 35% by 2030 (1,255,000 individuals); while the number of cases of compensated (n =325,900) and decompensated (n=45,000) cirrhosis; hepatocellular carcinoma (n=19,100); and liver-related deaths (n=16,700) is supposed to peak between 2028 and 2032. In strategy 2; treated cases increased over tenfold in 2020 (118,800 treated) as compared to 2013 (11,740 treated); with sustained virological response increased to 90% and treatment eligibility to 95%. Under this strategy; the number of infected individuals decreased by 90% between 2013 and 2030. Compared to the base case; liver-related deaths decreased by 70% by 2030; while hepatitis C virus-related liver cancer and decompensated cirrhosis decreased by 75 and 80%; respectively. Conclusions: While the incidence and prevalence of hepatitis C virus in Brazil are decreasing; cases of advanced liver disease continue to rise. Besides higher sustained virological response rates; new strategies focused on increasing the proportion of diagnosed patients and eligibility to treatment should be adopted in order to reduce the burden of hepatitis C virus infection in Brazil.
dc.description.indexMEDLINE
dc.identifier.citationBRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.19, n.4, p.363-368, 2015
dc.identifier.doi10.1016/j.bjid.2015.04.004
dc.identifier.eissn1678-4391
dc.identifier.issn1413-8670
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/11675
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsopenAccess
dc.rights.holderCopyright ELSEVIER SCIENCE BV
dc.subjectHCV
dc.subjectDisease burden
dc.subjectEpidemiology
dc.subjectIncidence
dc.subjectBrazil
dc.subject.otherhcv infection
dc.subject.otherfollow-up
dc.subject.othermortality
dc.subject.othercohort
dc.subject.othersurvival
dc.subject.otherribavirin
dc.subject.otheraddicts
dc.subject.otherlondon
dc.subject.otherusers
dc.subject.otherdeath
dc.subject.wosInfectious Diseases
dc.titleDisease burden of chronic hepatitis C in Brazil
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalFERREIRA, Paulo Roberto Abrao:Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, SP, Brazil
hcfmusp.author.externalBRANDAO-MELLO, Carlos Eduardo:Univ Fed Estado Rio Janeiro UNIRIO, Dept Gastroenterol, Rio De Janeiro, RJ, Brazil
hcfmusp.author.externalESTES, Chris:CDA, Louisville, CO USA
hcfmusp.author.externalGONCALES JUNIOR, Fernando Lopes:Univ Estadual Campinas, Fac Ciencias Med, Dept Clin Med, Disciplina Doencas Infecciosas,Grp Estudo Hepatit, Sao Paulo, SP, Brazil
hcfmusp.author.externalCOELHO, Henrique Sergio Moraes:Univ Fed Rio de Janeiro, Dept Clin Med, Rio De Janeiro, RJ, Brazil
hcfmusp.author.externalRAZAVI, Homie:CDA, Louisville, CO USA
hcfmusp.author.externalCHEINQUER, Hugo:Univ Fed Rio Grande do Sul, Hosp Clin, Porto Alegre, RS, Brazil
hcfmusp.author.externalWOLFF, Fernando Herz:Univ Fed Rio Grande do Sul, Hosp Clin, Porto Alegre, RS, Brazil
hcfmusp.author.externalFERRAZ, Maria Lucia Gomes:Univ Fed Sao Paulo, Div Gastroenterol, Sao Paulo, SP, Brazil
hcfmusp.citation.scopus14
hcfmusp.contributor.author-fmusphcMARIO GUIMARAES PESSOA
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.description.beginpage363
hcfmusp.description.endpage368
hcfmusp.description.issue4
hcfmusp.description.volume19
hcfmusp.origemWOS
hcfmusp.origem.pubmed26051505
hcfmusp.origem.scieloSCIELO:S1413-86702015000400363
hcfmusp.origem.scopus2-s2.0-84938204729
hcfmusp.origem.wosWOS:000358803200004
hcfmusp.publisher.cityAMSTERDAM
hcfmusp.publisher.countryNETHERLANDS
hcfmusp.relation.referenceBjornaas MA, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-8
hcfmusp.relation.referenceCampiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
hcfmusp.relation.referenceDavis GL, 2010, GASTROENTEROLOGY, V138, P513, DOI 10.1053/j.gastro.2009.09.067
hcfmusp.relation.referenceDeuffic-Burban S, 2012, GASTROENTEROLOGY, V143, P974, DOI 10.1053/j.gastro.2012.05.054
hcfmusp.relation.referenceENGSTROM A, 1991, INT J ADDICT, V26, P91
hcfmusp.relation.referenceFried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
hcfmusp.relation.referenceFrischer M, 1997, ADDICTION, V92, P419, DOI 10.1111/j.1360-0443.1997.tb03373.x
hcfmusp.relation.referenceHickman M, 2003, J URBAN HEALTH, V80, P274, DOI 10.1093/jurban/jtg030
hcfmusp.relation.referenceKamper-Jorgensen M, 2008, TRANSFUSION, V48, P2577, DOI 10.1111/j.1537-2995.2008.01881.x
hcfmusp.relation.referenceKikuchi L, 2013, ANTIVIR THER, V18, P445, DOI 10.3851/IMP2602
hcfmusp.relation.referenceNational STD/AIDs Programme Federal Ministry of Health, 2011, PUBL SECT INT BRAZ
hcfmusp.relation.referenceOPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x
hcfmusp.relation.referencePERUCCI CA, 1991, AM J PUBLIC HEALTH, V81, P1307, DOI 10.2105/AJPH.81.10.1307
hcfmusp.relation.referenceRazavi H, 2014, J VIRAL HEPATITIS, V21, P34, DOI 10.1111/jvh.12248
hcfmusp.relation.referenceShiffman ML, 2007, NEW ENGL J MED, V357, P124, DOI 10.1056/NEJMoa066403
hcfmusp.relation.referenceUnited Nations - Department of Economic and Social Affairs, 2012, 2012 REV WORLD POP P
hcfmusp.relation.referenceUnited Nations Department of Economic and Social Affairs Population Division, 2011, WORLD POP PROSP 2010, VI and II
hcfmusp.relation.referencevan der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication0baf66bd-afb9-4844-b40c-485b3c558f66
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublication.latestForDiscovery0baf66bd-afb9-4844-b40c-485b3c558f66
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_FERREIRA_Disease_burden_of_chronic_hepatitis_C_in_Brazil_2015.PDF
Tamanho:
995.99 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03